Value
9.1/10data confidence 20%| Component | Sub-score |
|---|---|
| P/S | 9.1 |
- ▸Attractively valued
FLGT · Why this verdict
Why Fulgent Genetics (FLGT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.5/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Short interest of 15% is flagged as justified alongside an elevated put/call ratio of 2.23, reflecting the market's bearish risk pricing. Risk breakdown | Short interest should fall below 10% and the put/call ratio should compress below 1.5 over the next 12 months. | →Stable |
| CounterHigh short interest into a catalyst-driven earnings event can set up a short squeeze if the beat streak continues, rather than confirming further downside. | ||
Quality score of 2.0 sits below the engine's 4.0 floor, driven by cash burn (FCF -33% of revenue) and a weak Piotroski F-Score of 3/9. Quality breakdown | Quality score should rise above 4.0 over the next 12 months as cash burn narrows and the Piotroski F-Score improves. | →Stable |
| CounterGenetic-testing and diagnostics companies can show temporary cash-burn spikes tied to lab-capacity investment or contract-testing volume swings that reverse quickly. | ||
The stock has already exceeded its target, with -24.6% remaining upside, driving the V9 asymmetry gate to fail at -1.64. Engine gate (failed) | The asymmetry ratio should turn positive, above 0, over the next 12 months as either price consolidates or the target is raised. | →Stable |
| CounterAn earnings catalyst in 27 days with a 3/4 beat streak could quickly raise the price target without requiring a price pullback. | ||
The company has beaten earnings in 3 of the last 4 quarters with a large average surprise (183%), and the engine flags a CATALYST edge ahead of earnings in 27 days, but analyst estimates have fallen 45.8% over the past 30 days. Catalyst breakdown | Estimates should stabilize or turn back upward, and the beat streak should continue at the July 31, 2026 report. | →Stable |
| CounterSharply falling estimates ahead of a print often precede a miss rather than a beat, undercutting the catalyst framing despite the historical beat streak. | ||
The setup is in RECOVERY from a death cross with improving MACD, but RSI is overbought at 73 within a confirmed downtrend, below the 200-MA with a -1.9%/30-day MA slope. Momentum breakdown | Price should reclaim and hold above the 200-day moving average over the next 12 months for the recovery thesis to be confirmed. | →Stable |
| CounterAn overbought RSI reading inside a confirmed downtrend is explicitly labeled by the engine as an overbought bear rally, suggesting this could be a temporary bounce rather than a genuine recovery. | ||
Short interest of 15% is flagged as justified alongside an elevated put/call ratio of 2.23, reflecting the market's bearish risk pricing.
→StableRisk breakdown
- Expectation
- Short interest should fall below 10% and the put/call ratio should compress below 1.5 over the next 12 months.
CounterHigh short interest into a catalyst-driven earnings event can set up a short squeeze if the beat streak continues, rather than confirming further downside.
Quality score of 2.0 sits below the engine's 4.0 floor, driven by cash burn (FCF -33% of revenue) and a weak Piotroski F-Score of 3/9.
→StableQuality breakdown
- Expectation
- Quality score should rise above 4.0 over the next 12 months as cash burn narrows and the Piotroski F-Score improves.
CounterGenetic-testing and diagnostics companies can show temporary cash-burn spikes tied to lab-capacity investment or contract-testing volume swings that reverse quickly.
The stock has already exceeded its target, with -24.6% remaining upside, driving the V9 asymmetry gate to fail at -1.64.
→StableEngine gate (failed)
- Expectation
- The asymmetry ratio should turn positive, above 0, over the next 12 months as either price consolidates or the target is raised.
CounterAn earnings catalyst in 27 days with a 3/4 beat streak could quickly raise the price target without requiring a price pullback.
The company has beaten earnings in 3 of the last 4 quarters with a large average surprise (183%), and the engine flags a CATALYST edge ahead of earnings in 27 days, but analyst estimates have fallen 45.8% over the past 30 days.
→StableCatalyst breakdown
- Expectation
- Estimates should stabilize or turn back upward, and the beat streak should continue at the July 31, 2026 report.
CounterSharply falling estimates ahead of a print often precede a miss rather than a beat, undercutting the catalyst framing despite the historical beat streak.
The setup is in RECOVERY from a death cross with improving MACD, but RSI is overbought at 73 within a confirmed downtrend, below the 200-MA with a -1.9%/30-day MA slope.
→StableMomentum breakdown
- Expectation
- Price should reclaim and hold above the 200-day moving average over the next 12 months for the recovery thesis to be confirmed.
CounterAn overbought RSI reading inside a confirmed downtrend is explicitly labeled by the engine as an overbought bear rally, suggesting this could be a temporary bounce rather than a genuine recovery.
TrendMatrix Research · core thesis
Engine thesis — one sentence
FLGT combines a historical earnings-beat catalyst with quality below the engine's minimum floor, a price already past target causing a negative asymmetry gate failure, falling analyst estimates, and a death-cross recovery attempt undercut by overbought technicals and elevated short/options positioning.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 3.7 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.7 |
| FCF quality | 0.0 |
| Moat | 3.2 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -33% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
- ▸Quality concerns
Growth
1.7/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 1.7 |
- ▸Declining revenue: -3%
Momentum
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 0.9 |
- ▸Overbought bear rally (RSI 77)
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -1.9%/30d — confirmed downtrend
Sentiment
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 3.1 |
| erm sentiment | 5.0 |
- ▸Below analyst target
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸Insider selling (low materiality) — $106,343 (0.018% of mkt cap)
Peer rank
5.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.8 |
| quality rank | 2.0 |
| growth rank | 1.3 |
Technical
1.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.1 |
| support resistance | 0.3 |
| 52w position | 3.8 |
Risk (lower is worse)
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 2.0 |
| days to cover | 4.8 |
| volatility | 4.8 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 7.7 |
| debt equity | 5.2 |
- ▸High short interest justified: 15%
- ▸Elevated put/call: 4.83
- ▸High IV: 142%
- ▸Above max pain $2
Catalyst
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 3.5 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:5.9>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:25d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.8=NEGATIVE
Warning (2)
- DEATH_CROSS:momentum=5.9>=5.0 recovering
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-1.77
Upside
-26.5%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 77
EdgeCatalyst-Driven — Earnings in 25d with 3/4 beat streak
SuitabilityAggressive — MCap $0.6B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.1 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-1.8=NEGATIVE.
The strongest dimensions are Value at 9.1, Catalyst at 6.3, and Momentum at 5.9; the weakest are Technical at 1.4, Growth at 1.7, and Quality at 2.0. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of -1.77 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Minimum Floor
Trip ifQuality score rises above 4.0, up from the current 2.0.
- P2Target Reached Negative Asymmetry
Trip ifAsymmetry ratio rises above 0, clearing the current -1.64 gate failure.
- P3Earnings Beat Catalyst With Falling Estimates
Trip ifAnalyst estimates stabilize and rise back above a -10% 30-day change, up from the current -45.8%.
- P4Death Cross Recovery With Overbought Technicals
Trip ifPrice falls more than 5% below the 200-day moving average, confirming the downtrend rather than a recovery.
- P5Elevated Short Interest And Options Risk
Trip ifShort interest falls below 10%, down from the current 15%.